$1.16
0.87%
Nasdaq, Sep 02, 10:00 pm CET
ISIN
US81362J1007
Symbol
VANI

Second Sight Medical Products, Inc. Stock price

$1.16
-0.24 17.14% 1M
+0.08 7.41% 6M
+0.00 0.00% YTD
-0.15 11.45% 1Y
-2.36 67.05% 3Y
-1.19 50.62% 5Y
-218.92 99.47% 10Y
-478.12 99.76% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
+0.01 0.87%

Key metrics

Basic
Market capitalization
$68.7m
Enterprise Value
$61.9m
Net debt
positive
Cash
$6.8m
Shares outstanding
59.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
14.0
Financial Health
Equity Ratio
42.4%
Return on Equity
-130.6%
ROCE
-120.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-26.4m | -
EBIT
$-26.8m | $-27.6m
Net Income
$-25.5m | $-23.9m
Free Cash Flow
$-23.1m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-5.9% | -
EBIT
-6.0% | -10.3%
Net Income
-5.5% | -3.8%
Free Cash Flow
-7.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.4
FCF per Share
$-0.4
Short interest
0.7%
Employees
37
Rev per Employee
$0.0
Show more

Is Second Sight Medical Products, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Second Sight Medical Products, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Second Sight Medical Products, Inc. forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Second Sight Medical Products, Inc. forecast:

Buy
88%
Hold
13%

Financial data from Second Sight Medical Products, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.31 9.31
5% 5%
-
- Research and Development Expense 17 17
7% 7%
-
-26 -26
6% 6%
-
- Depreciation and Amortization 0.40 0.40
8% 8%
-
EBIT (Operating Income) EBIT -27 -27
6% 6%
-
Net Profit -26 -26
5% 5%
-

In millions USD.

Don't miss a Thing! We will send you all news about Second Sight Medical Products, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Second Sight Medical Products, Inc. Stock News

Neutral
GlobeNewsWire
14 days ago
ALAMEDA, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. ( NASDAQ: VANI ) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present a company overview and conduct partnering meetings at the H.C. Wainwright 27th Annual Global Investment Conference, tak...
Neutral
GlobeNewsWire
20 days ago
Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clinical study of NPM-115
Positive
Seeking Alpha
4 months ago
Here's the next batch of weird science stocks that have market darling potential. I'm tracking five meme-worthy, deep science sectors: brain-computer interfaces, CRISPR/gene editing, organoids, programmable cell therapy, and room-temperature superconductors. Monitor each sector's stocks poised to soar if a major tech player announces a breakthrough.
More Second Sight Medical Products, Inc. News

Company Profile

Second Sight Medical Products, Inc. engages in the development, manufacture, and marketing of implantable visual prosthetics. It operates through the following geographical segments: United States, Italy, France, and China. The firm's product include Argus II Retinal Prosthesis System that treats outer retinal degenerations, such as retinitis pigmentosa, also referred to as RP. The company was founded by Alfred E. Mann, Aaron Mendelsohn, Sam Williams, Robert J. Greenberg, and Gunnar Bjorg in 1998 and is headquartered in Sylmar, CA.

Head office United States
CEO Adam Mendelsohn
Employees 37
Founded 2003
Website vivani.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today